98.20 +0.40 (0.41%)
After hours: 4:11PM EDT
|Bid||97.76 x 900|
|Ask||97.81 x 800|
|Day's Range||95.83 - 99.90|
|52 Week Range||64.72 - 125.59|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||537.36|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||111.33|
SAN DIEGO , Sept. 11, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the appointment of Leslie V. Norwalk to its Board of Directors. Ms. Norwalk formerly served as Acting ...
Lannett (LCI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Matt Abernethy, Chief Financial Officer, will present at the Baird 2019 Global Healthcare Conference at 8:30 a.m. ET on Wednesday, Sept. 4, 2019, in New York. Kevin Gorman, Chief Executive Officer, will present at the Morgan Stanley 17th Annual Healthcare Conference at 11:10 a.m. ET on Tuesday, Sept. 10, 2019, in New York. The live presentations will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com.
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Neurocrine Biosciences (NBIX).
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Neurocrine Biosciences, Inc. (NBIX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Achillion (ACHN) meets bottom-line estimates in the second quarter. The absence of an approved product results in no revenues in the quarter.
CEO of Neurocrine Biosciences Inc (30-Year Financial, Insider Trades) Kevin Charles Gorman (insider trades) sold 80,000 shares of NBIX on 08/08/2019 at an average price of $95.31 a share. Continue reading...
- New Drug Application (NDA) is supported by data from pivotal Phase 3 studies of nearly 800 patients - Clinical trials in women with heavy menstrual bleeding (HMB) associated with uterine fibroids showed ...
Neurocrine (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Dow Jones futures: Beyond Meat stock dived late on mixed results and a share offering. RingCentral, Chegg rallied on earnings after closing in buy range. Apple earnings are on tap.
Neurocrine (NBIX) delivered earnings and revenue surprises of 54.17% and 14.59%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
INGREZZA® (valbenazine) Second Quarter Net Product Sales of $180.5 Million with Approximately 31,600 TRx FDA Accepts Opicapone New Drug Application with PDUFA Date of April 26, 2020 Congenital Adrenal ...